Skip to content

Horizon Discovery Group enters exclusive partnership with C4X Discovery Holdings

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc, a pioneering drug discovery company, to validate targets and develop next-generation oncology drugs. The partnership aims to validate the novel synthetic lethal … Continued

T3 rate Cornerstone #1 in the razor subscription market

Sam Horti of T3 discusses how to take the hassle out of shave shopping with the best online subscription razors If you haven’t fallen victim to the hipster revolution, and favour a wet shave over electric, then you’ll need to buy razor blades – and that’s where a subscription service can help you. Forget the … Continued

Venn signs deal with Open Orphan to focus on rare diseases

The Irish Times covers the news of Venn’s latest strategic collaboration with Open Orphan DAC. Venn has established full-service clinical research programmes and activities in 27 different countries. The company seeks to increase its focus on rare diseases and assume a market-leading position.The firm also said it had issued £1 million (€1.1 million) in privately-held … Continued

CloudTrade – A Digital Transformation in the Invoicing World

Peter Smith from Spend Matters discusses the latest on Calculus investment, CloudTrade, with Non-Executive Chairman, Philip Padfield Last week I caught up with Philip Padfield, a non-executive Chairman with CloudTrade. He also introduced me to their new marketing head, Tara Burghardt. CloudTrade has been going since 2010 but seems to be slipping into a higher gear, … Continued

Success at the Open Banking Awards for Money Dashboard

Calculus Capital portfolio company Money Dashboard scooped three awards last night at the Open Banking Awards for: – Best use of data science for good – Best innovation for savings journey – Most innovative new feature as a force for making lives better This follows the announcement earlier yesterday that Money Dashboard has linked up … Continued

uniQure incorporates novel synthetic promoter developed by Synpromics in new preclinical target

Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than … Continued